Loading...
•
Jun 30, 2021
Reneo Pharmaceuticals Q2 2021 Earnings Report
Reneo Pharmaceuticals reported a net loss for Q2 2021 and provided an update on its clinical programs.
Key Takeaways
Reneo Pharmaceuticals reported a net loss of $9.2 million, or $0.43 per share, for the three months ended June 30, 2021. The company had $167.3 million in cash, cash equivalents and short-term investments as of June 30, 2021.
First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies.
Completed enrollment of study REN001-103 in patients with glycogen storage disease type V (McArdle disease).
Dosed 20 patients to date in study REN001-102 in patients with long-chain fatty acid oxidation disorder (LC-FAOD).
Enrolled 18 patients to date in the FORWARD study in patients with LC-FAOD.